Inhibitory effect of azelnidipine on sympathetic nerve activity in hypertensive patients Evaluation of different class effect of calcium channel blocker by using muscle sympathetic nerve activity
Not Applicable
- Conditions
- Primary Hypertension
- Registration Number
- JPRN-UMIN000009123
- Lead Sponsor
- Internal Medicine, Kanazawa University Hospital Disease Control and Homeostasis
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 20
Inclusion Criteria
Not provided
Exclusion Criteria
1.Patients who need drug medication for diabetes mellitus, heart failure or arrhythmia 2.Patients who have severe functional disturbance of liver or kidney 3.Patiens who have history of apoplexy or undergoing operation with artificial vessel 4.Patients of secondary hypertension 5.Patients whose systolic blood pressure is over 200mmHg or diastolic blood pressure is over 120mmHg
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Each effect of azelnidipine and amlodipine on blood pressure and sympathetic nerve activity in hypertensive patients, 8 weeks after beginning of each administration
- Secondary Outcome Measures
Name Time Method Each effect of azelnidipine and amlodipine on renal function, liver function, and cardiac function in hypertensive patients, 8 weeks after beginning of each administration